Identifying and managing inhibitor patients requiring orthopaedic surgery - The multidisciplinary team approach

Haemophilia, Supplement

Volumn 11, Issue 1, 2005, Pages 7-10

  Ludlam, Christopher ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Haemophilia; Haemostasis; Haemostatic agent; Inhibitors; Management; Orthopaedic surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; TRANEXAMIC ACID;

BLEEDING; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG HALF LIFE; HEMOPHILIA; HEMOSTASIS; HUMAN; INTERDISCIPLINARY COMMUNICATION; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; SAFETY; THROMBOGENICITY; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 27744503091     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01152.x     Document Type: Review

References (18)

1. Mizon P, Goudemand J, Jude B, Marey A. Myocardial infarction after FEIBA™ therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol 1992; 64: 309-11.
2. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.
3. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
4. Tjonnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
5. Smith MP, Ludlam CA, Collins PW et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86: 949-53.
6. Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in high-responder haemophilia patients. Haemophilia 2004; 10 (Suppl. 2): 46-9.
7. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities. Semin Hematol 2004; 41 (Suppl. 1): 109-16.
8. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
9. Tagariello G, Bisson R, Radossi P et al. Concurrent total hip and knee replacements in a patient with haemophilia with inhibitors using recombinant factor VIIa by continuous infusion. Haemophilia 2003; 9: 738-40.
10. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625-31.
11. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000; 26: 425-32.
12. Karayalcin G, Goldberg B, Cherrick I, Kurer C, Bierman F, Lanzkowsky P. Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor. Am J Pediatr Hematol Oncol 1993; 15: 416-9.
13. Chavin SI, Siegel DM, Rocco TA Jr, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med 1988; 85: 245-9.
14. Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777-85.
15. Hedner U, Kristensen H, Berntorp E, Ljung R, Petrini P, Tengborn L. Pharmacokinetics of rFVIIa in children [abstract]. Haemophilia 1998; 4: 244.
16. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
17. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
18. Schulman S, d'Oiron R, Martinowitz U et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S97-101.